

**FREE
CME ACTIVITY**

Jointly provided by
The France Foundation & Pulmonary Fibrosis
FOUNDATION

 **PILOT™** Pulmonary Fibrosis Identification:
Lessons for Optimizing Treatment

FACING IPF TOGETHER: A Case-Based Team Approach

CONNECTING THE MULTIDISCIPLINARY CARE TEAM AND PATIENTS



SATURDAY, OCTOBER 1, 2016 • 8:30 AM–1:00 PM

**Crowne Plaza Boston Newton Hotel • Charles Ballroom
320 Washington Street • Newton, Massachusetts**

Hosted by: THE BOSTON-PROVIDENCE PULMONARY FIBROSIS CARE CENTERS
The ILD Programs of MGH, BIDMC, SEMC and RIH

AGENDA:

SESSIONS FOR CLINICIANS AND PATIENTS/CAREGIVERS

- ▶ 8:30 AM Registration and Breakfast
- ▶ 9:00 AM **IPF Diagnosis and Treatment with Case Review**
- ▶ 10:45 AM Break
- ▶ 11:00 AM **The Patient Journey**
- ▶ 11:15 AM **What's on the Horizon:
Potential Therapies in Clinical Trials**
- ▶ 11:30 AM Breakout Sessions
 - ▶ **Problem Based Learning Cases for Clinicians**
 - ▶ **Patient/Caregiver Workshop**
- ▶ 1:00 PM Adjourn

Register at:

www.PILOTforIPF.org/boston

FACULTY:

ANDREW TAGER, MD (CHAIR)

Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Massachusetts General Hospital
Boston, Massachusetts

KEVIN R. FLAHERTY, MD (CO-CHAIR)

Professor of Medicine
University of Michigan Health System
Ann Arbor, Michigan

PETER LACAMERA, MD

Chief, Division of Pulmonary, Critical Care and Sleep
Medicine
Director, Interstitial Lung Disease Program
St. Elizabeth's Medical Center
Boston, Massachusetts

BARRY SHEA, MD

Director, Interstitial Lung Disease Program
Division of Pulmonary, Critical Care and Sleep Medicine
Rhode Island Hospital
Providence, Rhode Island

JOSEPH ZIBRAK, MD

Director, Interstitial Lung Disease Center
Pulmonary, Critical Care and Sleep Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Featuring a Pulmonary Fibrosis Foundation
Ambassador

**FREE
CME ACTIVITY**

Jointly provided by
The France Foundation & Pulmonary Fibrosis
FOUNDATION

 **PILOT™** Pulmonary Fibrosis Identification:
Lessons for Optimizing Treatment

FACING IPF TOGETHER: A Case-Based Team Approach

CONNECTING THE MULTIDISCIPLINARY CARE TEAM AND PATIENTS



SATURDAY, OCTOBER 1, 2016 • 8:30 AM–1:00 PM

**Crowne Plaza Boston Newton Hotel • Charles Ballroom
320 Washington Street • Newton, Massachusetts**

**Hosted by: THE BOSTON-PROVIDENCE PULMONARY FIBROSIS CARE CENTERS
The ILD Programs of MGH, BIDMC, SEMC and RIH**

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, thoracic radiologists, pathologists, fellows, nurse practitioners, physician assistants, and other health care providers who manage patients with IPF. It is also intended for patients and caregivers.

STATEMENT OF NEED

Diagnosis of IPF is difficult and requires multiple findings from several specialists. Awareness of guidelines and the criteria for diagnosis is incomplete for many pulmonologists and radiologists. Furthermore, pulmonologists underestimate the clinical impact of available treatments and have difficulty communicating the therapeutic impact of these agents on disease progression to patients. Clinical evidence guiding treatment decisions such as choice of therapy, combination therapy, and switching therapy is incomplete, requiring detailed discussions between patients and providers.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

- Apply current ATS/ERS criteria to the process for differentially diagnosing IPF.
- Integrate histopathologic with high-resolution computed tomography (HRCT) data in the diagnosis of IPF when necessary.
- Explain disease progression and the heterogeneity of the disease.
- Examine emerging research related to IPF treatment.
- Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients.
- Utilize dose modification to manage side effects in patients.
- Recognize treatment success, disease progression, and when/if to switch therapy.
- Collaborate with patients and/or caregivers in overcoming barriers to daily living.


Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Pulmonary Fibrosis Foundation. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The France Foundation designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy: In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use: TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment: This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

 TFF fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant of this activity in need of accommodation, please submit written requests to The France Foundation via fax at 860-434-5390.

Media Disclosure: Your registration, attendance at, and/or participation in this meeting constitutes consent to being photographed, videotaped, or recorded during the meeting by TFF, its educational collaborators, or anyone authorized on behalf of these organizations. You further authorize, without any compensation paid to you, the use of any photographs, videos, or recordings that contain your likeness, image, or voice in any educational, informational, commercial, or promotional materials produced and/or distributed by TFF, its educational collaborators, or anyone authorized by these organizations, as well as on any Internet sites maintained by any of these entities. Images/recordings used for these purposes will not be sold, and no personal information about you or the subject (other than event location and date) will be included in the production of any material.

Register at:

www.PILOTforIPF.org/boston